INCY vs ALKS vs JAZZ vs ACAD

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 31. 8% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Incyte Corporation (INCY) offers the better valuation at 15. 2x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

2x versus Alkermes plc at 25. 3x. On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 8. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +64.

4%, compared to +15. 2% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: JAZZ returned +45. 6% versus ACAD's -17. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 94% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 31. 8% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, ACAD leads at 25. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Incyte Corporation (INCY) is the more profitable company, earning 25.

0% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 25. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26. 1% versus 5. 3% for JAZZ. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 8.

8x forward P/E versus 50. 4x for ACADIA Pharmaceuticals Inc. — 41. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 55. 6% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Jazz Pharmaceuticals plc (JAZZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65)). Both have compounded well over 10 years (JAZZ: +45. 6%, ACAD: -17. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INCY is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock; ACAD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.